340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth

Blog: Putting 340B Program Growth in Context

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When appropriately contextualized, this data is evidence that the 340B program is one of the most consequential policy solutions to address high and rising drug prices, as well as ensure that drug companies contribute to the health care safety net in communities across this country,” the blog notes. The blo…

IRA Will Slow 340B Growth in 2026, Predicts Drug Channels’ Adam Fein - 340B Report

The Inflation Reduction Act (IRA) has created an “inflection point” that will slow 340B program growth in 2026, predicted an [...] The post IRA Will Slow 340B Growth in 2026, Predicts Drug Channels’ Adam Fein appeared first on 340B Report.

340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth

Whoa. The 340B Drug Pricing Program has once again given new meaning to the word “skyrocketing.” For 2024, discounted purchases under the 340B program reached a record $81.4 billion—an astounding $15.1 billion (+23%) higher than 2023. The gross-to-net difference between list prices and discounted 340B purchases—a proxy for funds available to covered entities—also grew, to $66.4 billion (+$6.0 billion). Hospitals again accounted for 87% of 340B p…